PsychedelicNewsBreaks – Microdose Psychedelic to Host February Molecular Masterclass: The LSD Conference

February 10, 2022 13:50:59

Microdose Psychedelic Insights, a cutting-edge media company focused on promoting content, financial analysis, and engaging events designed to drive the psychedelics industry into the forefront of modern medicine, announced that it will be hosting the Molecular Masterclass: LSD Conference next week. Microdose is hosting the event, scheduled for Feb. 17, 2022, in partnership with MindBio Therapeutics. The all-virtual conference is designed to offer a scientific deep dive into the dynamic field of LSD microdosing exploring the potential of LSD at the intersection of drug development and safety, clinical care and applications, law and regulation, business and markets, science and research, and history and culture. Presentations during the one-day event include “The History of That ‘Curious Molecule’” by Peter Van der Heyden, chief scientific officer at Psygen Industries, and William Leonard Pickard, former research associate in neurobiology at Harvard Medical School. Event participants can watch the presentation live and even participate in a question-and-answer session afterward. Other discussions include “The Therapeutic Use of LSD in Psychiatry,” “Posology and Tolerance to Regression,” “Safety and Efficacy of Lysergic Acid Diethylamide (LSD)-Assisted Psychotherapy,” “LSD Microdosing,” “Effect of Lysergic Acid Diethylamide (LSD) on Learning” and “The Effects of LSD on Creativity.” The event agenda also offers networking opportunities in group settings and one-on-one meetings. MindBio Therapeutics is a clinical-stage, drug-development company researching the medicinal use of psychedelic medicines to treat a range of debilitating mental health conditions.

To attend the event, visit https://ibn.fm/wxmBc

To view the full press release, visit https://ibn.fm/TkNFR

About Microdose Psychedelic Insights

Microdose Psychedelic Insights is a guide to the psychedelic medicine industry. With a vision to shift the world’s perception of psychedelic medicine, the company distribute and create the most compelling content, financial analysis, engaging events, and ground-breaking education to drive the psychedelics industry to the forefront of modern medicine. For more information about the company, visit www.Microdose.buzz.

About PsychedelicNewsWire

PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.

To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.PsychedelicNewsWire.com

Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer

Do you have questions or are you interested in working with PNW? Ask our Editor

PsychedelicNewsWire (PNW)
San Francisco, California
www.PsychedelicNewsWire.com
415.949.5050 Office
Editor@PsychedelicWire.com

PsychedelicNewsWire is part of the InvestorBrandNetwork.